Navigation Links
Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
Date:9/17/2012

GM-CSF gene, to enhance the immune response against cancer cells.

Hepatocellular Carcinoma: A Global Unmet Need
Hepatocellular carcinoma is the fifth most common cancer worldwide and the third leading cause of cancer death, with over 600,000 new cases diagnosed annually resulting in more than 90 percent mortality.  The annual incidence rate in the U.S., Europe, Japan and China are estimated to be 20,000, 55,000, 40,000 and 350,000 patients, respectively. The only treatment approved for HCC is sorafenib. There is no treatment approved for patients who fail sorafenib.

About Jennerex's Partners for JX-594
Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, holds an exclusive license to develop and commercialize JX-594 in Europe and neighboring countries. Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, holds an exclusive license to develop and commercialize JX-594 in South Korea, and Lee's Pharmaceutical Ltd. holds an exclusive license to develop and commercialize JX-594 in China.

Transgene, a member of the Institut Merieux Group, is a publicly traded French biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases, and has five compounds in clinical development: TG4010 and JX-594 (TG6006) having completed initial phase II trials, TG4001 in phase IIb trial, TG4040 in phase II trial and TG4023 in phase I trial. Transgene has concluded strategic agreements for the development of two of its immunotherapy products, an option agreement with Novartis for the development of TG4010 to treat various cancers, and an in-licensing agreement with U.S.-based Jennerex Biotherapeutics, Inc., to develop and market JX-594 (TG6006), an oncolytic product. Transgene has bio-manufacturi
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Jennerex Announces First Patient Treated in Phase 2 Clinical Trial of Intravenous Delivery JX-594 In Patients with Advanced Liver Cancer
2. Jennerex Appoints Dr. Laurent Fischer as President and Chief Executive Officer
3. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
4. Mettler Toledo Presents In-depth Guidance to Comply with New USP Chapters 41 and 1251 on Balances Used for Quantitative Analysis in the Pharma QC Lab
5. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
6. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
7. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
8. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
9. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
10. Grant & Eisenhofer Represents Key Whistleblower in Justice Dept.s $1.04 Billion Civil Settlement with GlaxoSmithKline
11. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... VeraTag(TM) Assays in Breast ... Cancer, SOUTH ... announced five posters to be,presented at the 30th San Antonio Breast Cancer Symposium ... details for,each embargoed session:, -- Friday, December 14th, 2007, 7.00 am ...
... Biotech today announced that 12,clinical studies of DOXIL(R) ... the 49th annual meeting of the American Society ... on December 8-11,2007., "We are very pleased ... Craig Tendler, M.D., Vice President, Medical Affairs,Oncology/Nephrology, Ortho ...
Cached Medicine Technology:Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 2Monogram Announces Posters to be Presented at the 30th San Antonio Breast Cancer Symposium 3Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 2Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 3Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 4Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 5Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 6Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 7Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 8Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting 9
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
(Date:4/17/2014)... a review published in the April issue of ... Feinstein Institute for Medical Research, says it,s time to ... approach to treating sepsis, which kills millions worldwide ... occurs when molecules released into the bloodstream to fight ... Inflammation is necessary for maintaining good health without ...
(Date:4/17/2014)... personnel who served in Iraq and Afghanistan and ... (TBI) were compared to military personnel without TBI ... in measures of overall disability, cognitive function, post-traumatic ... reported in an article in Journal of ... Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... YORK, NY (April 16, 2014) The cause of ... a new study proposes that neurons may be mistaken ... immune system, similar to the way autoimmune diseases like ... the body,s cells. The study was published April 16, ... a new, and likely controversial, idea in Parkinson,s disease; ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Is Parkinson's an autoimmune disease? 2
... much within a generation and nearly 1000 British women are ... issued a warning// that mixtures of chemicals present in day ... of breast cancer. ,Synthetic estrogens have caught the ... to the female sex hormone estrogen. Estrogen which is an ...
... taking the death toll in the capital to 33 Tuesday, ... the mosquito-borne viral disease showing no signs of abating. ... 83 new patients admitted in the city hospitals since Monday. ... 55-year-old Pritam of Faridabad town close to the national capital. ...
... Treatment outcomes vary widely and depend on which state, ... the finding of a new report//. ,The report, ... have a 69 percent lower risk of dying at ... the difference between the best- and worst-performing hospitals has ...
... needs this year according to state and federal officials who ... a shot. ,Annemarie Beardsworth, adult-immunization manager at the ... Rhode Island's public flu clinics, which started on Oct. 2, ... regular shipments. ,Beardsworth said, "Anyone who wants to ...
... United States researchers have explained the recent improvements in the ... slowing// the onset of paralysis. It is observed that people ... in charge of breathing actually stop working. Despite all the ... reasons that cause the disease. ,During the study, ...
... drug funding agency has confirmed that herceptin, a drug ... spite of ongoing criticism// over the decision. The deputy ... drug is highly expensive and funding could not be ... and has been arrived at after complete investigation of ...
Cached Medicine News:Health News:One More Victim Succumbs to Dengue in Delhi 2Health News:Hospital Outcome Linked to its Quality 2
... Injectable was designed to provide the surgeon with ... of surgical complications during cataract and retinal surgery. ... small and medium sized pupils which allows expansion ... iris sphincter during surgery, and allows the pupil ...
... Flow Unit is a flexible, total solution. , ... operating theaters since 1983. A major part of ... extensive experience from all the different areas of ... , ,Kojair Tech Oy is a comprehensive supplier. ...
Provides stable positioning of the knee during surgery....
BRAT 2 Autologous Blood Recovery System gives performance, speed, versatility, and quality processing. , ,The BRAT 2 is now available with on-board Vacuum, programmability, plasma sequestration, Data...
Medicine Products: